摘要
目的:探讨血清人附睾蛋白4(HE4)、甲壳质酶蛋白40(YKL-40)在子宫内膜癌的表达及临床意义。方法:用酶联免疫吸附试验检测健康妇女、子宫内膜增生及子宫内膜癌患者血清中HE4、YKL-40的水平。结果:(1)健康妇女、子宫内膜增生患者及子宫内膜癌患者术前血清中HE4表达中位数分别为15.75、30.12、105.67pmol/L;YKL-40的表达中位数分别为39.6、42.8、100.5μg/L;子宫内膜癌组HE4、YKL-40的表达水平均高于前两组,差异有统计学意义(P<0.05),前两组的差异无统计学意义;子宫内膜癌患者术后血清中HE4、YKL-40中位数分别为23.52pmol/L、30.9μg/L,明显低于术前(P<0.05);(2)子宫内膜癌患者术前血清HE4浓度、YKL-40浓度与FIGO分期呈正相关关系。结论:子宫内膜癌血清HE4、YKL-40水平升高,可作为子宫内膜癌血清学标记物,是子宫内膜癌的早期辅助诊断、疗效评估、随访检测的客观指标,可用于指导临床的综合治疗。
Objective：To explore the expressions and signiiicance ot serum human epldidymis protein 4 （HE4） , YKL40 in patients with endometrial cancer. Methods：The enzymelinked immuno-sorbent assay（ELISA） technique was applied to detect serum HE4 and YKL40 levels in healthy women and patients with endometrial hyperplasia, and endometrial cancer. Results： （ 1 ） In healthy women, patients with endometrial hyperplasia, preoperative endometrial cancer,the serum HE4 median levels were 15.75,30.12,105.67pmol/L respectively. The serum YKL-40 median levels were 39.6,42.8,100.5 μg/L respectively. The preoperative median levels of HEd,YKL-40 in endometrial cancer group were significantly higher than those of the former two groups （P〈0.05）. No statistically significant difference was found between the former two groups（ P〉0.05 ）. In endometrial cancer group, the median postoperative HE4, YKL-40 levels were 23.52pmol/L, 30.9 μg/L, which were significantly lower than preoperative levels （P 〈0.05 ）. （2） In endometrial cancer group,the preoperative serum HE4 and YKL40 levels positively correlated with the FIGO stage （ P〈0.05 ）. Conclusion ： Serum HE4, YKL-40 levels can be seen as biomarkers of the endometrial carcinoma.
出处
《现代妇产科进展》
CSCD
北大核心
2011年第5期377-380,共4页
Progress in Obstetrics and Gynecology
基金
2010年宁夏科技攻关项目[No:宁科计字(2010)168]
